Skip to content

News

New Ovarian Cancer Dream Team to Research DNA Repair Therapies

New Ovarian Cancer Dream Team to Research DNA Repair Therapies

Ovarian Cancer Research Fund, Ovarian Cancer National Alliance and National Ovarian Cancer Coalition Team-Up to Fund Game-Changing Ovarian Cancer Research Today the members of the new Stand Up To Cancer-Ovarian Cancer Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition Translational Research Dream Team were announced. The Dream Team will focus on “DNA Repair Therapies for … Continued

OCRA News

Announcing the Ovarian Cancer Dream Team!

Announcing the Ovarian Cancer Dream Team!

April 20, 2015:   The Ovarian Cancer Dream Team has been chosen! The Dream Team will focus on “DNA Repair Therapies for Ovarian Cancer,” building on recent advances that have identified DNA repair as a common weakness in ovarian cancer. Researchers will also explore the prevention and early detection of ovarian cancer by developing a … Continued

OCRA News

New Recommendations for Ovarian Cancer Prevention

New Recommendations for Ovarian Cancer Prevention

(April 16, 2015) The Society of Gynecologic Oncology has published recommendations for prevention of ovarian cancer in Cancer.  Strategies include oral contraceptive use and tubal sterilization, as well as genetic counseling and testing for women from high-risk families. Read the abstract in ACS Journals.

Research

BRCA Cancer Risk Differs With Type and Location of Mutations

BRCA Cancer Risk Differs With Type and Location of Mutations

(April 15, 2015) Doctors have long recognized that women with mutations in two particular genes – BRCA1 and BRCA2 – have a higher risk of breast and ovarian cancer. Now they are starting to figure out which mutations are worse than others. They have even discovered that some of these mutations may reduce a woman’s … Continued

Research

Rucaparib Receives Breakthrough Therapy Designation from FDA

Rucaparib Receives Breakthrough Therapy Designation from FDA

(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer. Rucaparib is an oral, small-molecule PARP inhibitor developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors that have BRCA mutations and other DNA deficiencies commonly referred to as “BRCA-like.” An FDA-designated “breakthrough … Continued

Research

Rachel Zoe and Molly Sims Return to Host Ovarian Cancer Res...

Rachel Zoe and Molly Sims Return to Host Ovarian Cancer Research Fund’s 2nd Annual Super Saturday LA

Designer Charity Sale Offers Day-Long Luxury Experiences for the Whole Family Los Angeles, CA (April 14, 2015) – Rachel Zoe and Rodger Berman with Molly Sims and Scott Stuber will return to host Ovarian Cancer Research Fund’s (OCRF) 2nd Annual Super Saturday LA. The day-long designer charity sale, now held annually in Los Angeles as … Continued

Events

The New York Times Publishes OCRF’s Letter to the Editor 3/...

The New York Times Publishes OCRF’s Letter to the Editor 3/30/15

In response to the “Angelina Jolie Pitt: Diary of a Surgery,” Op-Ed, published in The New York Times on March 24, 2015, OCRF co-wrote a Letter to the Editor along with Ovarian Cancer National Alliance, reminding readers that there is still no early detection method for ovarian cancer. We’re grateful to once again have the … Continued

OCRA News

Microenvironment Regulates Tumor Suppressor miRNA

Microenvironment Regulates Tumor Suppressor miRNA

(April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused methylation mediated decrease in the expression of miR-193b in the tumor cells. … Continued

Research

Population Distribution of Lifetime Risk of Ovarian Cancer ...

Population Distribution of Lifetime Risk of Ovarian Cancer in the US

(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population.  In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher ovarian cancer risk due to both genetic and lifestyle factors. Leigh Pierce, PhD and … Continued

Research

Our Response to Angelina

Our Response to Angelina

Angelina Jolie Pitt recently announced that she has had her ovaries and fallopian tubes removed in order to reduce her risk of ovarian cancer. Ms. Jolie Pitt had previous shared that she has a mutation in the BRCA gene, which increases her risk of breast and ovarian cancers. The Alliance received many calls and requests … Continued

OCRA News

Intraperitoneal Chemo Associated with Long-Term Survival Ad...

Intraperitoneal Chemo Associated with Long-Term Survival Advantage

(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer.  The advantage of IP over intravenous chemotherapy extends beyond 10 years, and IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number … Continued

Research

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.